We found that cisplatin dose-dependently reduced the cell viability, and the tBHQ pretreatment significantly attenuated the cisplatin-induced viability inhibition (Additional file 1: Fig. S1D), suggesting that NRF2 activation may confer cisplatin resistance in the cancer cells. Here, NFE2L2 is linked to cancer.